MannKind Corporation (MNKD)
Company Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes.
It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.
The company has a license and collaboration agreement with United Therapeutics Corporation.
It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions.
MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
| Country | United States |
| IPO Date | Jul 28, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 403 |
| CEO | Dr. Michael E. Castagna Pharm.D. |
Contact Details
Address: 30930 Russell Ranch Road Danbury, California United States | |
| Website | https://www.mannkindcorp.com |
Stock Details
| Ticker Symbol | MNKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899460 |
| CUSIP Number | 56400P706 |
| ISIN Number | US56400P7069 |
| Employer ID | 13-3607736 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael E. Castagna Pharm.D. | Chief Executive Officer & Director |
| Christopher B. Prentiss M.B.A. | Chief Financial Officer |
| Dr. Burkhard Blank M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
| Dr. David B. Thomson J.D., Ph.D. | Executive Vice President, General Counsel & Secretary |
| Dr. Kevin Kaiserman M.D. | Senior Vice President & Therapeutic Area Head of Endocrine Diseases |
| Dr. Stuart A. Tross Ph.D. | Executive Vice President of Human Resources |
| John F. Bedard | Senior Vice President of Worldwide Regulatory Affairs |
| Lauren M. Sabella | Executive Vice President of Operations |
| Rosabel Realica Alinaya CPA | Vice President of Investor Relations & Treasury |
| Sanjay Singh M.B.A. | Executive Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 27, 2025 | 4 | Filing |
| May 27, 2025 | 4/A | [Amend] Filing |
| May 20, 2025 | 4 | Filing |
| May 20, 2025 | 4 | Filing |
| May 20, 2025 | 4 | Filing |
| May 20, 2025 | 4 | Filing |
| May 19, 2025 | 8-K | Current Report |
| May 16, 2025 | 4 | Filing |
| May 16, 2025 | 4 | Filing |
| May 16, 2025 | 4 | Filing |